-
1Academic Journal
Συγγραφείς: S. Yu. Kalinchenko, I. A. Tyuzikov, L. O. Vorslov, Yu. A. Tishova, С. Ю. Калинченко, Игорь Адамович Тюзиков, Л. О. Ворслов, Ю. А. Тишова
Πηγή: Andrology and Genital Surgery; Том 15, № 3 (2014); 42-51 ; Андрология и генитальная хирургия; Том 15, № 3 (2014); 42-51 ; 2412-8902 ; 2070-9781 ; 10.17650/2070-9781-2014-3
Θεματικοί όροι: андрогенозаместительная терапия, cardiovascular diseases, cardiovascular risk, evidence-based research, safety, androgen replacement therapy, сердечно-сосудистые заболевания, сердечно-сосудистый риск, доказательные исследования, безопасность
Περιγραφή αρχείου: application/pdf
Relation: https://agx.abvpress.ru/jour/article/view/106/100; Карчикян С.И. Об эссенциальной гипертонии и ее лечении на Кисловодском курорте. Клин мед 1930;8(2):49–58.; Глухенький Т.Т. Лечение гипертонии эндокринными препаратами. Врач дело 1946; 11–12:919–22.; Walker T.С. Use of testosterone propionate and estrogenic substances in treatment of essential hypertension, angina pectoris and peripheral vascular diseases. J Clin Endocrinol 1942;2:560–8.; Jaffe M.D. Effect of testosterone cypionate on postexercise ST segment depression. Br Heart J 1977;39(11):1217–22.; English K.M., Steeds R.P., Jones T.H. et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation 2000; 102(16):1906–11.; Zhang L., Wu S., Ruan Y. et al. Testosterone suppresses oxidative stress via androgen receptorindependent pathway in murine cardiomyocytes. Mol Med Rep 2011;4(6):1183–8.; Lee A.M., Chu L.W., Chong C.S. et al. Relationship between symptoms of androgen deficiency and psychological factors and quality of life among Chinese men. Int J Androl 2010;33(5):755–63.; Bredt D.S., Snyder S.H. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 1990;87(2):682–5.; Stuehr D.J., Kwon N.S., Nathan C.F. et al. N omega-hydroxy-L-arginine is an intermediate in the biosynthesis of nitric oxide from L-arginine. J Biol Chem 1991;266(10): 6259–63.; Zhao C., Moon du G., Park J.K. Effect of testosterone undecanoate on hematological profiles, blood lipid and viscosity and plasma testosterone level in castrated rabbits. Can Urol Assoc J 2013;7(3–4):221–5.; Tylińska M., Broncel M. The relationship between testosterone deficiency and metabolic syndrome in obese men. Pol Merkur Lekarski 2013;34(199):24–8.; Rubinow K.B., Vaisar T., Tang C. et al. Testosterone replacement in hypogonadal men alters the HDL proteome but not HDL cholesterol efflux capacity. J Lipid Res 2012;53(7):1376–83.; Monroe A.K., Dobs A.S. The effect of androgens on lipids. Curr Opin Endocrinol Diabetes Obes 2013;20(2):132–9.; Wu F.C., von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003;24(2):183–217.; Miner M., Barkin J., Rosenberg M.T. Testosterone deficiency: myth, facts, and controversy. Can J Urol 2014;21(3):39–54.; Maganty A., Osterberg E.C., Ramasamy R. Hypogonadism and testosterone therapy: associations with cardiovascular risk. Am J Mens Health 2014;pii: 1557988314540933. [Epub ahead of print].; Kelly D.M., Jones T.H. Testosterone and cardiovascular risk in men. Front Horm Res 2014;43:1–20.; Traish A.M. Adverse health effects of testosterone deficiency (TD) in men. Steroids 2014;88С:106–16.; Zitzmann M., Mattern A., Hanisch J. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med 2013;10(2):579–88.; Toma M., McAlister F.A., Coglianese E.E. et al. Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail 2012; 5(3):315–21.; Corona G., Rastrelli G., Monami M. et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a metaanalytic study. Eur J Endocrinol 2011;165(5): 687–701.; Araujo A.B., Dixon J.M., Suarez E.A. et al. Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96(10):3007–19.; Ruige J.B., Mahmoud A.M., De Bacquer D., Kaufman J.M. Endogenous testosterone and cardiovascular disease in healthy men: a metaanalysis. Heart 2011;97(11):870–5.; Corona G., Monami M., Rastrelli G. et al. Testosterone and metabolic syndrome: a metaanalysis study. J Sex Med 2011;8(1):272–83.; Tan W.S., Ng C.J., Khoo E.M. et al. The triad of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome: findings from a multi-ethnic Asian men study (The Subang Men’s Health Study). Aging Male 2011;14(4):231–6.; Bhasin S., Cunningham G.R., Hayes F.J. et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536–59.; Dandona P., Rosenberg M.T. A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract 2010;64:682–96.; Dohle G.R., Arver S., Bettocchi C. et al. Guidelines on Male Hypogonadism. EAU, 2014.; Wang C., Nieschlag E., Swerdloff R. et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008;159(5):507–14.; Hak A.E., Witteman J.C., de Jong F.H. et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 2002;87(8):3632–9.; Marin P., Holmäng S., Gusrafsson C. et al. Androgen treatment of abdominally obese men. Obes Res 1993;1(4):245–51.; Kalinchenko S.Y., Tishova Y.A., Mskhalaya G.J. et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal nien with the metabolic syndrome: the double-blinded placebo-controlled Moscow srudy. Clin Endocrinol (Oxf) 2010;73(5):602–12.; Jones T.H., Arver S., Behre H.M. et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011;34:828–37.; Haring R., Baumeister S.E., Volzke H. et al. Prospective inverse associations of sex hormone concentrations in men with biomarkers of inflammation and oxidative stress. J Androl 2012;33:944–50.; Baillargeon J., Urban R.J., Kuo Y.F. et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother 2014;48(9):1138–44.; Scovell J., Ramasamy R., Kovac J.R. A critical analysis of testosterone supplementation therapy and cardiovascular risk in elderly men. Can Urol Assoc J 2014; 8(5–6):356–7.; Martínez-Jabaloyas J.M.; DE-SDT study group. Testosterone deficiency in patients with erectile dysfunction: when should a higher cardiovascular risk be considered? J Sex Med 2014;11(8):2083–91.; Hackett G., Kirby M., Sinclair A.J. Testosterone deficiency, cardiac health, and older men. Int J Endocrinol 2014;2014: 143763.; Moncada I. Testosterone and men’s quality of life. Aging Male 2006;9(4):189–93.; Snyder P.J., Peachey H., Berlin J.A. et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000;85(8):2670–7.; Wang C., Alexander G., Berman N. et al. Testosterone replacement therapy improves mood in hypogonadal men – a clinical research center study. J Clin Endocrinol Metab 1996;81(10):3578–83.; Wang C., Cunningham G., Dobs A. et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004;89(5):2085–98.; Yassin A.A., Saad F. Improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J Sex Med 2007;4:497–501.; Hackett G., Cole N., Bhartia M. et al. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: The BLAST Study. J Sex Med 2014;11(3):840–56.; He J., Bhasin S., Binder E.F. et al. Cardiometabolic risks during anabolic hormone supplementation in older men. Obesity (Silver Spring) 2013;21(5):968–75.; Corona G., Monami M., Rastrelli G. et al. Type 2 diabetes mellitus and testosterone: A meta-analysis study. Int J Androl 2011; 34(6 Pt 1):528–40.; Cauley J.A., Gutai J.P., Kuller L.H., Dai W.S. Usefulness of sex steroid hormone levels in predicting coronary artery disease in men. Am J Cardiol 1981;60(10):771–7.; Basaria S., Coviello A.D., Travison T.G. et al. Adverse events associated with testosterone administration. N Engl J Med 2010;363(2):109–22.; Ho C.C., Tong S.F., Low W.Y. et al. A randomized, double-blind, placebocontrolled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU Int 2012;110(2): 260–5.; Khaw K.T., Dowsett M., Folkerd E. et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPICNorfolk) Prospective Population Srudy. Circulacion 2007;116(23):2694–701.; Menke A., Guallar E., Robrmann S. et al. Sex steroid hormone concentrations and risk of death in US men. Am J Epidemiol 2010; 171(5):583–92.; Schooling C.M. Testosterone and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 2014;21(3):202–8.; Merza Z., Blumsohn A., Mah P.M. et al. Double-blind placebo-controlled study of testosterone patch therapy on bone turn over in men with borderline hypogonadism. Int J Androl 2006;29(3):81–91.; Svartberg J., Agledahl I., Figenschau Y. et al. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res 2008;20(4):378–87.; Aversa A., Bruzziches R., Francomano D. et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with lateonset hypogonadism and metabolic syndrome: results from a 24-month, randomized, doubleblind, placebo-controlled study. J Sex Med 2010;7(10):3495–503.; Svartberg J., Aasebø U., Hjalmarsen A. et al. Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial. Respir Med 2004;98(9):906–13.; Hoyos C.M., Yee B.J., Phillips C.L. et al. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol 2012;167(4):531–41.; Tan R.S., Cook K.R., Reilly W.G. High Estrogen in men after injectable testosterone therapy: the low Т experience. Am J Mens Health 2014. pii: 1557988314539000.; www.fda.gov.; Vigen R., O’Donnell O., Barоn A. et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013;310(17):1829–36.; Finkle W.D., Greenland S., Ridgeway G.K. et al. Increased risks of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS ONE 2014; 9(1):e85805.; Xu L., Freeman G., Cowling B. et al. Testosterone therapy and cardiovascular events among men: a systematic review and metaanalysis of placebo-controlled trials. BMC Med 2013;11:108.; Morgentaler A., Traish A., Kacker R. Deaths and cardiovascular events in men receiving testosterone. JAMA 2014;311(9):961–2.; Morales A. Testosterone deficiency syndrome and cardiovascular health: Looking carefully at the evidence. Can Urol Assoc J 2014;8(1–2):34–5.; Morgentaler A. Testosterone, cardiovascular risk and hormonophobia. J Sex Med 2014;11(6):1362–6.; Page S.T. Testosterone, cardiovascular disease, and mortality in men: living in the dark. Lancet Diabetes Endocrinol 2014; 2(8):609–11.; Seftel A.D., Morgentaler A. Does testosterone increase the risk of a cardiovascular event? J Urol 2014. pii: S0022-5347(14)03349-7.; Morgentaler A., Lunenfeld B. Testosterone and cardiovascular risk: world’s experts take unprecedented action to correct misinformation. Aging Male 2014;17(2):63–5.; Calof O.M., Singh A.B., Lee M.L. et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebocontrolled trials. J Gerontol Biol Med Sci 2005;60(11):1451–7.; Haddad R.M., Kennedy C.C., Caples S.M. et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007;82(1):29–39.; Gruenewald D.A., Matsumoto A.M. Testosterone supplementation therapy for older men: potential benefits and risks. Am Geriatr Soc 2003;51(1):101–5.; Lunenfeld B., Mskhalaya G., Kalinchenko S., Tishova Y. Recommendations on the diagnosis, treatment and monitoring of late-onset hypogonadism in men – a suggested update. Aging Male 2013;16(4):143–58.; Fernández-Balsells M.M., Murad M.H., Lane M. et al. Сlinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010;95(6):2560–75.; Dobs A.S., Meikle A.W., Arver S. et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with biweekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999;84(10):3469–78.; Jones T.H., Saad F. The effects of testosterone on risk factors for, and the mediators of the atherosclerotic process. Atherosclerosis 2009;207(2):318–27.; Chrysant S.G. Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. Curr Hypertens Rep 2013;15(5):475–83.; Yeap B.B., Alfonso H., Chubb S.A. et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. J Clin Endocrinol Metab 2014;99(1): 9–18.; Ramasamy R., Kovac J.R., Scovell J.M. et al. Words of wisdom. Re: In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. Eur Urol 2014; 65(4):844–5.; Ajayi A.A., Mathur R., Halushka P.V. Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation 1995; 91(11):2742–7.; Kunnas T., Solakivi T., Huuskonen K. et al. Hematocrit and the risk of coronary heart disease mortality in the TAMRISK study, a 28-year follow-up. Prev Med 2009;49(1):45–7.; Sorlie P.D., Garcia-Palmieri M.R., Costas R. Jr. et al. Hematocrit and risk of coronary heart disease: The Puerto Rico Health Program. Am Heart J 1981;101(4):456–61.; Залманов А.С. Тайная мудрость человеческого организма. М., 1963.; Радзинский В.Е. Акушерская агрессия. М., 2011.; https://agx.abvpress.ru/jour/article/view/106
-
2Academic Journal
Συγγραφείς: A. Kamalov A., M. Chaly Ye., R. Vasilevsky P., А. Камалов А., М. Чалый Е., Р. Василевский П.
Πηγή: Bulletin of Siberian Medicine; Том 11, № 6 (2012); 195-197 ; Бюллетень сибирской медицины; Том 11, № 6 (2012); 195-197 ; 1819-3684 ; 1682-0363 ; 10.20538/1682-0363-2012-11-6
Θεματικοί όροι: screening, late onset hypogonadism, testosterone, presecretion, prostata gland, man, androgen replacement therapy, urinology, скрининг, возрастной гипогонадизм, тестостерон, гормон, предстательная железа, мужчина, андрогенозаместительная терапия, урология
Περιγραφή αρχείου: application/pdf
Relation: https://bulletin.tomsk.ru/jour/article/view/902/704; Верткин А.С., Калинченко С.Ю. Приобретенный возрастной дефицит андрогенов // Мед. газета. 2006. № 17. С. 2—3.; Гамидов С.И., Иремашвили В.В. Метаболический синдром в урологии. М.: Инсайт Полиграфик, 2010. 200 с.; Гамидов С.И. Современная урология может обеспечить высокое качество жизни пациентов с возрастным гипогонадизмом: актуальное интервью // Эффективная фармакотерапия (репринт). 2012. № 1. С. 3—6.; Гончаров Н.П. и др. Свободный тестостерон в слюне как диагностический маркер андрогенного статуса мужчин // Андрология и генитальная хирургия. 2006. № 3. С. 32—38.; Каррузерс М. Революция тестостерона. М.: МЕДпресс-информ, 2007. 224 с.; Михайличенко В.В. и др. Патогенез, диагностика и лечение возрастного андрогенного дефицита у мужчин // Андрология и генитальная хирургия. 2005. № 2. С. 60—62.; Ebert T. Clinical experience testosterone therapy, prostate safety // The Aging Male. 2004. № 7. Р. 304—311.; Morales A. Andropause or symptomatic late-onset hypogonadism // The Aging Male. 2004. № 7. Р. 297—303.; Mulligan T., Frick M.F. et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study // Int. J. Clin. Pract. 2006. V. 60. Р. 762—769.; Orshal J.M., Khalil R.A. Gender sex hormones, and vascu-lar tone // Am. J. Physiol. Regul. Integr. Comp. Physiol. 2004. V. 286. 233—249.; Shabsigh R. Hypogonadism and erectile dysfunction: the role for testosterone therapy // Int. J. Impot. Res. 2003. V. 15. Р. 9—13.; Thompson J., Khalil R. A. Gender differences in the regulation of vascular tone // Clin. Exp. Pharmacol. Physiol. 2003. 30. Р. 1—15.; https://bulletin.tomsk.ru/jour/article/view/902
-
3Academic Journal
Συγγραφείς: Камалов, А., Чалый, М., Василевский, Родион
Θεματικοί όροι: СКРИНИНГ, ВОЗРАСТНОЙ ГИПОГОНАДИЗМ, ТЕСТОСТЕРОН, ГОРМОН, ПРЕДСТАТЕЛЬНАЯ ЖЕЛЕЗА, МУЖЧИНА, АНДРОГЕНОЗАМЕСТИТЕЛЬНАЯ ТЕРАПИЯ, УРОЛОГИЯ
Περιγραφή αρχείου: text/html
-
4Academic Journal
Πηγή: Бюллетень сибирской медицины.
Θεματικοί όροι: СКРИНИНГ, ВОЗРАСТНОЙ ГИПОГОНАДИЗМ, ТЕСТОСТЕРОН, ГОРМОН, ПРЕДСТАТЕЛЬНАЯ ЖЕЛЕЗА, МУЖЧИНА, АНДРОГЕНОЗАМЕСТИТЕЛЬНАЯ ТЕРАПИЯ, УРОЛОГИЯ, 3. Good health
Περιγραφή αρχείου: text/html
